

Mauricio Tohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1460889/publications.pdf>

Version: 2024-02-01

150
papers

7,391
citations

101543

36
h-index

62596

80
g-index

222
all docs

222
docs citations

222
times ranked

5137
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of the COVID-19 mental health international for the general population (COMET-G) study. European Neuropsychopharmacology, 2022, 54, 21-40.	0.7	84
2	Chronobiologically-based sub-groups in bipolar I disorder: A latent profile analysis. Journal of Affective Disorders, 2022, 299, 691-697.	4.1	2
3	Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response. Journal of Affective Disorders, 2022, 300, 41-49.	4.1	6
4	Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses. European Neuropsychopharmacology, 2022, 54, 100-115.	0.7	43
5	Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder. Acta Psychiatrica Scandinavica, 2022, 145, 615-627.	4.5	9
6	Long-term morbidity in major affective and schizoaffective disorders following hospitalization in first psychotic episodes. Acta Psychiatrica Scandinavica, 2021, 143, 50-60.	4.5	1
7	Long-term treatment of bipolar disorder type I: A systematic and critical review of clinical guidelines with derived practice algorithms. Bipolar Disorders, 2021, 23, 324-340.	1.9	27
8	Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature Review. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 515-531.	2.2	4
9	Using Machine Learning Imputed Outcomes to Assess Drug-Dependent Risk of Self-Harm in Patients with Bipolar Disorder: A Comparative Effectiveness Study. JMIR Mental Health, 2021, 8, e24522.	3.3	3
10	Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar I Disorder in Adults: An Evidence-Based Review of Recent Data. Drug Design, Development and Therapy, 2021, Volume 15, 2005-2012.	4.3	8
11	Increased Glutamate Plus Glutamine in the Right Middle Cingulate in Early Schizophrenia but Not in Bipolar Psychosis: A Whole Brain 1H-MRS Study. Frontiers in Psychiatry, 2021, 12, 660850.	2.6	8
12	The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial. Current Medical Research and Opinion, 2021, 37, 1635-1643.	1.9	14
13	Characteristics of Hispanics Referred to Coordinated Specialty Care for First-Episode Psychosis and Factors Associated With Enrollment. Psychiatric Services, 2021, 72, 1407-1414.	2.0	4
14	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. Bipolar Disorders, 2021, 23, 659-678.	1.9	27
15	Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome. Journal of Psychiatric Research, 2021, 140, 205-213.	3.1	5
16	Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. Psychiatry Research, 2021, 305, 114194.	3.3	1
17	Prodromal features in first-psychotic episodes of major affective and schizoaffective disorders. Journal of Affective Disorders, 2021, 295, 1251-1258.	4.1	4
18	Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies. International Clinical Psychopharmacology, 2021, 36, 76-83.	1.7	10

#	ARTICLE	IF	CITATIONS
19	Development of a Patient-Centered Software System to Facilitate Effective Management of Bipolar Disorder. <i>Psychopharmacology Bulletin</i> , 2021, 51, 8-19.	0.0	0
20	The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study. <i>Journal of Affective Disorders</i> , 2020, 266, 772-781.	4.1	13
21	Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study. <i>Bipolar Disorders</i> , 2020, 22, 372-384.	1.9	201
22	Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder. <i>Psychoneuroendocrinology</i> , 2020, 112, 104511.	2.7	17
23	The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 230-256.	2.1	38
24	<p></p>The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 481-497.	1.9	71
25	Glutamatergic hypo-function in the left superior and middle temporal gyri in early schizophrenia: a data-driven three-dimensional proton spectroscopic imaging study. <i>Neuropsychopharmacology</i> , 2020, 45, 1851-1859.	5.4	8
26	Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response. <i>Journal of Affective Disorders</i> , 2020, 273, 131-137.	4.1	7
27	Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	12
28	Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. <i>Journal of Affective Disorders</i> , 2019, 257, 17-22.	4.1	26
29	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 720-740.	1.9	71
30	Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. <i>Journal of Affective Disorders</i> , 2019, 259, 164-172.	4.1	13
31	Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials. <i>Acta Neuropsychiatrica</i> , 2019, 31, 230-234.	2.1	2
32	What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/ICSLI Task Force on treatment with lithium. <i>Bipolar Disorders</i> , 2019, 21, 394-409.	1.9	98
33	Comparison of 71 bipolar disorder pharmacotherapies for kidney disorder risk: The potential hazards of polypharmacy. <i>Journal of Affective Disorders</i> , 2019, 252, 201-211.	4.1	8
34	Functional outcome assessment in bipolar disorder: A systematic literature review. <i>Bipolar Disorders</i> , 2019, 21, 194-214.	1.9	45
35	Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. <i>Journal of Affective Disorders</i> , 2019, 246, 126-131.	4.1	11
36	Preferences of Information Dissemination on Treatment for Bipolar Disorder: Patient-Centered Focus Group Study. <i>JMIR Mental Health</i> , 2019, 6, e12848.	3.3	8

#	ARTICLE	IF	CITATIONS
37	Early Intervention in Bipolar Disorder. American Journal of Psychiatry, 2018, 175, 411-426.	7.2	218
38	Severity of symptoms in mania—clinical guidelines and study design implications. Bipolar Disorders, 2018, 20, 171-172.	1.9	0
39	Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial. Journal of Affective Disorders, 2018, 225, 563-568.	4.1	18
40	Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. Acta Neuropsychiatrica, 2018, 30, 297-305.	2.1	10
41	Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. Australian and New Zealand Journal of Psychiatry, 2018, 52, 994-1002.	2.3	3
42	Aggression among 216 patients with a first-psychotic episode of bipolar I disorder. International Journal of Bipolar Disorders, 2018, 6, 18.	2.2	13
43	Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. Bipolar Disorders, 2018, 21, 350-360.	1.9	5
44	Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disorders. Bipolar Disorders, 2018, 20, 761-771.	1.9	6
45	White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2017, 51, 355-365.	2.3	22
46	Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder. Depression and Anxiety, 2017, 34, 281-290.	4.1	12
47	Bipolar mixed features — Results from the comparative effectiveness for bipolar disorder (Bipolar) Tj ETQq1 1 0.784314 rgBTj/Overlock	4.1	10
48	Treatment Guidelines in Bipolar Disorders and the Importance of Proper Clinical Trial Design. International Journal of Neuropsychopharmacology, 2017, 20, 95-97.	2.1	5
49	Systemic challenges in bipolar disorder management: A patient-centered approach. Bipolar Disorders, 2017, 19, 676-688.	1.9	19
50	The need to change from a phenomenological to a target engagement approach. Bipolar Disorders, 2017, 19, 513-514.	1.9	1
51	Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. Journal of Affective Disorders, 2017, 223, 146-152.	4.1	18
52	Increased Activity or Energy as a Primary Criterion for the Diagnosis of Bipolar Mania in DSM-5: Findings From the STEP-BD Study. American Journal of Psychiatry, 2017, 174, 70-76.	7.2	27
53	Cultural influences on suicide in Japan. Psychiatry and Clinical Neurosciences, 2017, 71, 2-5.	1.8	24
54	Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine. Journal of Clinical Psychiatry, 2017, 78, e1158-e1166.	2.2	6

#	ARTICLE	IF	CITATIONS
55	Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder. primary care companion for CNS disorders, The, 2017, 19, .	0.6	5
56	Acute risk factors for suicide attempts and death: prospective findings from the <scp>STEP</scp>â€œ<scp>BD</scp> study. Bipolar Disorders, 2016, 18, 363-372.	1.9	40
57	In Memoriam - Vivek Singh. Journal of Affective Disorders, 2016, 193, 144.	4.1	0
58	Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study. Journal of Affective Disorders, 2016, 205, 159-164.	4.1	7
59	Hypothyroidism risk compared among nine common bipolar disorder therapies in a large <scp>US</scp> cohort. Bipolar Disorders, 2016, 18, 247-260.	1.9	29
60	Harnessing the potential of community-based participatory research approaches in bipolar disorder. International Journal of Bipolar Disorders, 2016, 4, 4.	2.2	33
61	Analysis of bipolar maintenance treatment with lithium versus olanzapine utilizing Multiâ€state Outcome Analysis of Treatments (<scp>MOAT</scp>). Bipolar Disorders, 2016, 18, 282-287.	1.9	10
62	A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report. Journal of Affective Disorders, 2016, 192, 212-218.	4.1	22
63	Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness). Journal of Clinical Psychiatry, 2016, 77, 90-99.	2.2	69
64	The McLean-Harvard First-Episode Project. Journal of Clinical Psychiatry, 2016, 77, 781-788.	2.2	15
65	Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar <scp>CHOICE</scp>). Bipolar Disorders, 2015, 17, 212-223.	1.9	77
66	Use of Electroconvulsive Therapy in Bipolar Depression. American Journal of Psychiatry, 2015, 172, 3-5.	7.2	3
67	Psychotherapy use in bipolar disorder: Association with functioning and illness severity. Australian and New Zealand Journal of Psychiatry, 2015, 49, 453-461.	2.3	21
68	Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. Schizophrenia Bulletin, 2015, 41, 1237-1247.	4.3	45
69	Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. European Child and Adolescent Psychiatry, 2015, 24, 1485-1496.	4.7	18
70	Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology, 2014, 39, 2549-2559.	5.4	40
71	Psychiatric collaborations in the Hispanic world. Revista De PsiquiatrÃa Y Salud Mental (English) Tj ETQq1 1 0.784314 rgBT /Qverlock 10	0.3	1
72	Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the Bipolar CHOICE trial. Journal of Affective Disorders, 2014, 161, 30-35.	4.1	18

#	ARTICLE	IF	CITATIONS
73	Psychiatric collaborations in the Hispanic world. Revista De Psiquiatr�a Y Salud Mental, 2014, 7, 155-156.	1.8	6
74	Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 114-127.	1.6	60
75	Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5. Journal of Affective Disorders, 2014, 168, 136-141.	4.1	28
76	Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. Journal of Affective Disorders, 2014, 164, 57-62.	4.1	37
77	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	7.2	579
78	Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. International Journal of Methods in Psychiatric Research, 2013, 22, 46-58.	2.1	78
79	Credibility of industry-funded clinical trials. International Journal of Neuropsychopharmacology, 2013, 16, 1879-1884.	2.1	3
80	Predicting Diagnostic Change Among Patients Diagnosed With First-EpisodeDSM-IV-TRMajor Depressive Disorder With Psychotic Features. Journal of Clinical Psychiatry, 2013, 74, 723-731.	2.2	33
81	Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. British Journal of Psychiatry, 2012, 201, 376-382.	2.8	103
82	Two-year outcomes in first-episode psychotic depression. Journal of Affective Disorders, 2012, 136, 1-8.	4.1	129
83	Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disorders, 2011, 13, 87-98.	1.9	155
84	The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disorders, 2009, 11, 453-473.	1.9	401
85	Olanzapine versus lithium in the acute treatment of bipolar mania: A double-blind, randomized, controlled trial. Journal of Affective Disorders, 2008, 105, 101-108.	4.1	62
86	Clinical Trials in Bipolar Mania. Archives of General Psychiatry, 2008, 65, 252.	12.3	14
87	Olanzapine as Maintenance Therapy in Patients with Bipolar I Disorder. Progress in Neurotherapeutics and Neuropsychopharmacology, 2007, 2, 225-238.	0.0	0
88	Collaborations between academic psychiatry and the pharmaceutical industry: A perspective from industry. Epidemiologia E Psichiatria Sociale, 2007, 16, 197-198.	0.9	4
89	Conflicts of interest and the credibility of psychiatric research. World Psychiatry, 2007, 6, 33-4.	10.4	8
90	Diagnostic and Clinical Management Approaches to Bipolar Depression, Bipolar II and Their Comorbidities. , 2006, , 193-234.		0

#	ARTICLE	IF	CITATIONS
91	The Scope of Bipolar Disorders. , 2006, , 1-8.		1
92	Treatment for Bipolar Disorder in Older Adults. , 2006, , 301-311.		0
93	The Primacy of Mania. , 2006, , 169-192.		4
94	Bipolarity in Women: Therapeutic Issues. , 2006, , 235-277.		3
95	Pediatric Bipolar Disorder: The Promise of Psychopharmacotherapy. , 2006, , 279-299.		0
96	Psychosocial Interventions in Bipolar Disorders: Rationale and Effectiveness. , 2006, , 313-332.		1
97	The Pivotal Role of Psychoeducation in the Long-Term Treatment of Bipolar Disorder. , 2006, , 333-345.		2
98	The Role of Treatment Setting in the Pharmacotherapy of Bipolar Disorder. , 2006, , 347-352.		1
99	Suicide Prevention. , 2006, , 353-365.		1
100	Principles of Caring for Bipolar Patients. , 2006, , 367-387.		0
101	Lithium Treatment: Focus on Long-Term Prophylaxis. , 2006, , 9-26.		0
102	Pharmacological Profile and Clinical Utility of Lamotrigine in Bipolar Disorders. , 2006, , 43-62.		0
103	Carbamazepine, Other Anticonvulsants and Augmenting Agents. , 2006, , 63-83.		4
104	Haloperidol and Risperidone in Mania. , 2006, , 105-123.		2
105	A Comparison of "Second Generation Antipsychotics" in the Treatment for Bipolar Disorder: Focus on Clozapine, Quetiapine, Ziprasidone and Aripiprazole. , 2006, , 125-134.		1
106	Complex Combination Therapy: The Evolution Toward Rational Polypharmacy in Lithium-Resistant Bipolar Illness. , 2006, , 135-167.		4
107	Olanzapine in Treatment for Bipolar Disorder. , 2006, , 85-103.		0
108	Valproate: Clinical Pharmacological Profile. , 2006, , 27-42.		1

#	ARTICLE	IF	CITATIONS
109	Influence of sub-syndromal symptoms after remission from manic or mixed episodes. British Journal of Psychiatry, 2006, 189, 515-519.	2.8	78
110	Differential Efficacy of Olanzapine and Lithium in Preventing Manic or Mixed Recurrence in Patients With Bipolar I Disorder Based on Number of Previous Manic or Mixed Episodes. Journal of Clinical Psychiatry, 2006, 67, 95-101.	2.2	70
111	Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disorders, 2005, 7, 68-76.	1.9	43
112	Olanzapine Versus Lithium in the Maintenance Treatment of Bipolar Disorder: A 12-Month, Randomized, Double-Blind, Controlled Clinical Trial. American Journal of Psychiatry, 2005, 162, 1281-1290.	7.2	327
113	Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser <i>v.</i> mood stabiliser alone. British Journal of Psychiatry, 2004, 184, 337-345.	2.8	288
114	Double-Blind Comparison of the Continued Use of Antipsychotic Treatment Versus Its Discontinuation in Remitted Manic Patients. American Journal of Psychiatry, 2004, 161, 169-171.	7.2	125
115	A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania. Archives of General Psychiatry, 2003, 60, 1218.	12.3	198
116	Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression. Archives of General Psychiatry, 2003, 60, 1079.	12.3	797
117	The McLean-Harvard First-Episode Mania Study: Prediction of Recovery and First Recurrence. American Journal of Psychiatry, 2003, 160, 2099-2107.	7.2	412
118	Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disorders, 2001, 3, 165-173.	1.9	59
119	Onset of action of antipsychotics in the treatment of mania. Bipolar Disorders, 2000, 2, 261-268.	1.9	29
120	Functional impairment and cognition in bipolar disorder. Psychiatric Quarterly, 2000, 71, 309-329.	2.1	187
121	Unipolar Mania Reconsidered: Evidence from an Elderly Cohort. British Journal of Psychiatry, 1994, 164, 547-549.	2.8	37
122	The significance of mania in old age. Reviews in Clinical Gerontology, 1992, 2, 39-43.	0.5	3
123	Outcome in Mania. Archives of General Psychiatry, 1990, 47, 1106.	12.3	507
124	Four-year follow-up of twenty-four first-episode manic patients. Journal of Affective Disorders, 1990, 19, 79-86.	4.1	120
125	Symptoms and Functioning of Patients With Bipolar Disorder Six Months After Hospitalization. Psychiatric Services, 1988, 39, 652-657.	2.0	89
126	Preparation for the Certification Examination*. Canadian Journal of Psychiatry, 1983, 28, 471-474.	1.9	3

#	ARTICLE	IF	CITATIONS
127	Mental Health Services Research. , 0, , 165-179.		2
128	Studying the Natural History of Psychopathology. , 0, , 213-238.		3
129	The Epidemiology of Alcohol Use, Abuse, and Dependence. , 0, , 459-477.		3
130	Introduction to Epidemiologic Research Methods. , 0, , 1-33.		9
131	Epidemiology of Mood and Anxiety Disorders in Children and Adolescents. , 0, , 657-704.		50
132	Epidemiology of Psychosis with Special Reference to Schizophrenia. , 0, , 363-387.		10
133	The Developmental Epidemiology of Psychiatric Disorders. , 0, , 239-255.		2
134	Epidemiology of Depressive and Anxiety Disorders. , 0, , 389-426.		20
135	The Epidemiology of Child and Adolescent Mental Disorders. , 0, , 629-655.		16
136	Symptom Scales and Diagnostic Schedules in Adult Psychiatry. , 0, , 273-332.		25
137	Methods in Psychiatric Genetics. , 0, , 65-130.		12
138	The Pharmacoepidemiology of Psychiatric Medications. , 0, , 181-194.		2
139	Birth and Development of Psychiatric Interviews. , 0, , 257-271.		4
140	Peering into the Future of Psychiatric Epidemiology. , 0, , 195-211.		0
141	The Epidemiology of First-Onset Mania. , 0, , 445-458.		5
142	The National Comorbidity Survey. , 0, , 343-362.		69
143	Personality Disorders: Epidemiological Findings, Methods, and Concepts. , 0, , 563-599.		2
144	Epidemiology of Drug Dependence. , 0, , 479-561.		27

#	ARTICLE	IF	CITATIONS
145	Epidemiology of Bipolar Disorder. , 0, , 427-444.		31
146	Analysis of Categorized Data: Use of the Odds Ratio as a Measure of Association. , 0, , 35-63.		5
147	DSM-IV and Psychiatric Epidemiology. , 0, , 333-342.		4
148	Validity: Definitions and Applications to Psychiatric Research. , 0, , 149-163.		5
149	Epidemiology and Geriatric Psychiatry. , 0, , 601-628.		2
150	Psychiatric Epidemiology. , 0, , 401-432.		0